{"title":"CSF a - β38在日本研究和临床队列中的临床应用。","authors":"Tamao Tsukie, Kensaku Kasuga, Masataka Kikuchi, Takanobu Ishiguro, Akinori Miyashita, Osamu Onodera, Takeshi Iwatsubo, Takeshi Ikeuchi","doi":"10.1002/dad2.70125","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Previous studies have reported that cerebrospinal fluid (CSF) amyloid beta (Aβ42/Aβ38) performs comparably to Aβ42/Aβ40 in predicting amyloid positron emission tomography (PET) positivity in White cohorts. However, this finding has not been validated in diverse populations. Moreover, the utility of CSF Aβ38 in diagnosing various neurological diseases has not been fully understood.</p><p><strong>Methods: </strong>We analyzed CSF Aβ38, Aβ40, Aβ42, phosphorylated tau181, and neurofilament light chain in Japanese research and clinical cohorts with Alzheimer's clinical syndrome (ACS) or non-ACS.</p><p><strong>Results: </strong>CSF Aβ42/Aβ38 predicted amyloid PET positivity comparably to Aβ42/Aβ40. The levels of CSF Aβ38 were significantly lower in patients with progressive supranuclear palsy (PSP) and idiopathic normal pressure hydrocephalus (iNPH) than in those with other diseases.</p><p><strong>Discussion: </strong>We validated the high diagnostic performance of CSF Aβ42/Aβ38 in Japanese patients with AD. CSF Aβ38 reduction may be a characteristic feature of PSP and iNPH.</p><p><strong>Highlights: </strong>The diagnostic value of cerebrospinal fluid (CSF) amyloid beta (Aβ)38 was examined in Japanese research and clinical cohorts.CSF Aβ42/Aβ38 and Aβ42/Aβ40 showed comparable performance to detect brain Aβ deposition.CSF Aβ42/Aβ38 and Aβ42/Aβ40 discordant group showed a characteristic profile.CSF Aβ38 and Aβ40 were prominently decreased in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus.</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 2","pages":"e70125"},"PeriodicalIF":4.0000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100496/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts.\",\"authors\":\"Tamao Tsukie, Kensaku Kasuga, Masataka Kikuchi, Takanobu Ishiguro, Akinori Miyashita, Osamu Onodera, Takeshi Iwatsubo, Takeshi Ikeuchi\",\"doi\":\"10.1002/dad2.70125\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Previous studies have reported that cerebrospinal fluid (CSF) amyloid beta (Aβ42/Aβ38) performs comparably to Aβ42/Aβ40 in predicting amyloid positron emission tomography (PET) positivity in White cohorts. However, this finding has not been validated in diverse populations. Moreover, the utility of CSF Aβ38 in diagnosing various neurological diseases has not been fully understood.</p><p><strong>Methods: </strong>We analyzed CSF Aβ38, Aβ40, Aβ42, phosphorylated tau181, and neurofilament light chain in Japanese research and clinical cohorts with Alzheimer's clinical syndrome (ACS) or non-ACS.</p><p><strong>Results: </strong>CSF Aβ42/Aβ38 predicted amyloid PET positivity comparably to Aβ42/Aβ40. The levels of CSF Aβ38 were significantly lower in patients with progressive supranuclear palsy (PSP) and idiopathic normal pressure hydrocephalus (iNPH) than in those with other diseases.</p><p><strong>Discussion: </strong>We validated the high diagnostic performance of CSF Aβ42/Aβ38 in Japanese patients with AD. CSF Aβ38 reduction may be a characteristic feature of PSP and iNPH.</p><p><strong>Highlights: </strong>The diagnostic value of cerebrospinal fluid (CSF) amyloid beta (Aβ)38 was examined in Japanese research and clinical cohorts.CSF Aβ42/Aβ38 and Aβ42/Aβ40 showed comparable performance to detect brain Aβ deposition.CSF Aβ42/Aβ38 and Aβ42/Aβ40 discordant group showed a characteristic profile.CSF Aβ38 and Aβ40 were prominently decreased in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus.</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"17 2\",\"pages\":\"e70125\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100496/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.70125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
先前的研究报道了脑脊液（CSF）淀粉样蛋白β (Aβ42/Aβ38)在预测白人队列中淀粉样蛋白正电子发射断层扫描（PET）阳性方面的表现与Aβ42/Aβ40相当。然而，这一发现尚未在不同的人群中得到证实。此外，脑脊液Aβ38在诊断各种神经系统疾病中的作用尚未完全了解。方法：我们分析了日本研究和阿尔茨海默临床综合征（ACS）或非ACS患者的脑脊液a - β38、a - β40、a - β42、磷酸化tau181和神经丝轻链。结果：脑脊液Aβ42/Aβ38预测淀粉样蛋白PET阳性与Aβ42/Aβ40相当。进行性核上性麻痹（PSP）和特发性常压脑积水（iNPH）患者脑脊液Aβ38水平明显低于其他疾病患者。讨论：我们验证了CSF a - β42/ a - β38在日本AD患者中的高诊断性能。脑脊液a - β38减少可能是PSP和iNPH的特征。重点：脑脊液（CSF）淀粉样蛋白β (Aβ)38的诊断价值在日本的研究和临床队列中进行了检验。脑脊液Aβ42/Aβ38和Aβ42/Aβ40检测脑内Aβ沉积的性能相当。脑脊液a - β42/ a - β38和a - β42/ a - β40不一致组表现出特征性特征。脑脊液Aβ38和Aβ40在进行性核上性麻痹和特发性常压脑积水中显著降低。
Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts.
Introduction: Previous studies have reported that cerebrospinal fluid (CSF) amyloid beta (Aβ42/Aβ38) performs comparably to Aβ42/Aβ40 in predicting amyloid positron emission tomography (PET) positivity in White cohorts. However, this finding has not been validated in diverse populations. Moreover, the utility of CSF Aβ38 in diagnosing various neurological diseases has not been fully understood.
Methods: We analyzed CSF Aβ38, Aβ40, Aβ42, phosphorylated tau181, and neurofilament light chain in Japanese research and clinical cohorts with Alzheimer's clinical syndrome (ACS) or non-ACS.
Results: CSF Aβ42/Aβ38 predicted amyloid PET positivity comparably to Aβ42/Aβ40. The levels of CSF Aβ38 were significantly lower in patients with progressive supranuclear palsy (PSP) and idiopathic normal pressure hydrocephalus (iNPH) than in those with other diseases.
Discussion: We validated the high diagnostic performance of CSF Aβ42/Aβ38 in Japanese patients with AD. CSF Aβ38 reduction may be a characteristic feature of PSP and iNPH.
Highlights: The diagnostic value of cerebrospinal fluid (CSF) amyloid beta (Aβ)38 was examined in Japanese research and clinical cohorts.CSF Aβ42/Aβ38 and Aβ42/Aβ40 showed comparable performance to detect brain Aβ deposition.CSF Aβ42/Aβ38 and Aβ42/Aβ40 discordant group showed a characteristic profile.CSF Aβ38 and Aβ40 were prominently decreased in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus.
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
